NASDAQ:ADRO - Aduro BioTech Stock Price, Forecast & News

Aduro BioTech trades on the NASDAQ under the ticker symbol "ADRO."

Aduro BioTech Inc (NASDAQ:ADRO) posted its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.23) by $0.03. The biotechnology company had revenue of $4.80 million for the quarter, compared to analysts' expectations of $4.55 million. Aduro BioTech had a negative return on equity of 78.64% and a negative net margin of 544.94%. View Aduro BioTech's Earnings History.

Aduro BioTech is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Aduro BioTech.

7 brokers have issued twelve-month target prices for Aduro BioTech's shares. Their forecasts range from $4.00 to $9.00. On average, they anticipate Aduro BioTech's stock price to reach $6.50 in the next year. This suggests a possible upside of 364.3% from the stock's current price. View Analyst Price Targets for Aduro BioTech.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aduro BioTech in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Aduro BioTech.

News coverage about ADRO stock has trended negative recently, InfoTrie reports. The research group scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aduro BioTech earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Aduro BioTech.

Some companies that are related to Aduro BioTech include Xenon Pharmaceuticals (XENE), CytoDyn (CYDY), Lexicon Pharmaceuticals (LXRX), Catalyst Pharmaceuticals (CPRX), AnaptysBio (ANAB), BioSpecifics Technologies (BSTC), Aptorum Group (APM), Atreca (BCEL), Urovant Sciences (UROV), Verrica Pharmaceuticals (VRCA), Progenics Pharmaceuticals (PGNX), Lannett (LCI), Innate Pharma (IPHYF), Avedro (AVDR) and AMAG Pharmaceuticals (AMAG).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aduro BioTech investors own include EXACT Sciences (EXAS), Regulus Therapeutics (RGLS), Flexion Therapeutics (FLXN), Paratek Pharmaceuticals (PRTK), PTC Therapeutics (PTCT), MDxHealth (MXDHF), Juno Therapeutics (JUNO), CareDx (CDNA), Alibaba Group (BABA) and Cerus (CERS).

(ADRO) raised $119 million in an IPO on Wednesday, April 15th 2015. The company issued 7,000,000 shares at $17.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Aduro BioTech's stock is owned by many different of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.48%). Company insiders that own Aduro BioTech stock include Blaine Templeman, Celeste Ferber, Elsas Andrea Van, Jennifer Lew, Natalie Sacks and Stephen T Isaacs. View Institutional Ownership Trends for Aduro BioTech.

ADRO stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A.. Company insiders that have sold Aduro BioTech company stock in the last year include Blaine Templeman, Celeste Ferber, Elsas Andrea Van, Jennifer Lew and Stephen T Isaacs. View Insider Buying and Selling for Aduro BioTech.

Shares of ADRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ADRO stock can currently be purchased for approximately $1.40.

Aduro BioTech has a market capitalization of $112.72 million and generates $15.09 million in revenue each year. The biotechnology company earns $-95,360,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. Aduro BioTech employs 152 workers across the globe.View Additional Information About Aduro BioTech.

The official website for Aduro BioTech is http://www.aduro.com/.

Aduro BioTech's mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The biotechnology company can be reached via phone at 510-848-4400 or via email at [email protected]